EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Synthetic Approaches to the New Drugs Approved during 2023

Scott P France iD, Erick A Lindsey, Emma L McInturff iD, Simon Berritt iD, Jacob DeForest iD, Andrew C Flick iD, Sarah Fink iD, Tony S Gibson iD, Kaitlyn Gray iD, Aran K Hubbell iD, Amber M Johnson, Yiyang Liu iD und 3 weitere

Journal of Medicinal Chemistry · 13.02.2025 · 68 (3) · 2147-2182

DOI: 10.1021/acs.jmedchem.4c02079 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 03.02.2025. Verfasst von Scott P France und 14 weiteren Autor:innen. Beteiligte Einrichtung: Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States. Hauptthemen laut MEDLINE: Drug Approval. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 229 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This review is the next installment of an annual series that discusses the synthetic routes to access 28 small molecule drugs that were approved worldwide in 2023. A brief description of each drug's mechanism of action, the history of its discovery and development, and the synthetic approaches published in primary or patent literature that were most likely used for clinical studies or development are included. Synthetic chemistry, used to convert complex intermediates to active compounds or build a new drug from basic building block chemicals, is critical to delivery of new drugs and treatments for disease to patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalHumansDrug Discovery

Autor:innen und Institutionen

  • Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Takeda San Diego, 9265 Town Center Drive, San Diego, California 92121, United States.
  • Chemical Research and Development, Pfizer, Inc., Groton, Connecticut 06340, United States.
  • Medicine Design, Pfizer, Inc., Groton, Connecticut 06340, United States.
  • Medicine Design, Pfizer, Inc., La Jolla, California 92121, United States.
  • Crosswalk Therapeutics, Cambridge, Massachusetts 02139, United States.

ORCID-Profile: Scott P France, Emma L McInturff, Simon Berritt, Jacob DeForest, Andrew C Flick, Sarah Fink, Tony S Gibson, Kaitlyn Gray, Aran K Hubbell, Yiyang Liu, Zhiyao Zhou

Zitieren

APA

France, S. P., Lindsey, E. A., McInturff, E. L., Berritt, S., DeForest, J., Flick, A. C., Fink, S., Gibson, T. S., Gray, K., Hubbell, A. K., Johnson, A. M., Liu, Y., Mahapatra, S., Watson, R. B., & Zhou, Z. (2025). Synthetic Approaches to the New Drugs Approved during 2023. Journal of Medicinal Chemistry, 68(3), 2147-2182. https://doi.org/10.1021/acs.jmedchem.4c02079

Vancouver

France SP, Lindsey EA, McInturff EL, Berritt S, DeForest J, Flick AC, et al. Synthetic Approaches to the New Drugs Approved during 2023. Journal of Medicinal Chemistry. 2025;68(3):2147-2182. doi:10.1021/acs.jmedchem.4c02079

BibTeX
@article{France2025,
  author = {France, Scott P and Lindsey, Erick A and McInturff, Emma L and Berritt, Simon and DeForest, Jacob and Flick, Andrew C and Fink, Sarah and Gibson, Tony S and Gray, Kaitlyn and Hubbell, Aran K and Johnson, Amber M and Liu, Yiyang and Mahapatra, Subham and Watson, Rebecca B and Zhou, Zhiyao},
  title = {Synthetic Approaches to the New Drugs Approved during 2023},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  volume = {68},
  number = {3},
  pages = {2147--2182},
  doi = {10.1021/acs.jmedchem.4c02079}
}
Kostenlos starten →